Hypertrophic Cardiomyopathy Clinical Trial

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Summary

The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) [New York Heart Association (NYHA) Functional Class II or III].

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines as below:
Left ventricular outflow tract (LVOT) peak gradient ≥ 30 mm Hg and ≥ 50 mm Hg after Valsalva or after exercise
Left ventricular ejection fraction (LVEF) ≥ 55% at rest
New York Heart Association (NYHA) functional class II or III symptoms

Exclusion Criteria:

A known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM
Documented obstructive coronary artery disease or history of myocardial infarction
A history of resuscitated sudden cardiac arrest or life-threatening ventricular arrhythmia within 6 months prior to screening
An implantable cardioverter defibrillator (ICD) or pacemaker, or another contraindication for cardiac magnetic resonance imaging (CMR)

Note: Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Hypertrophic Cardiomyopathy

Phase:

Phase 4

Estimated Enrollment:

100

Study ID:

NCT06112743

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 73 Locations for this study

See Locations Near You

Cedars Sinai Medical Center
West Hollywood California, 90048, United States More Info
Florian Rader, Site 0087
Contact
310-967-3846
Piedmont Hospital
Atlanta Georgia, 30309, United States More Info
Rahul Loungani, Site 0003
Contact
803-553-1103
Local Institution - 0091
Honolulu Hawaii, 96813, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States More Info
Albree Tower-Rader, Site 0093
Contact
617-724-5434
University Hospitals Cleveland Medical Center - 11100 Euclid Ave
Cleveland Ohio, 44106, United States More Info
Imran Rashid, Site 0090
Contact
216-844-3800
Allegheny General Hospital
Pittsburgh Pennsylvania, 15212, United States More Info
Victor Farah, Site 0086
Contact
901-484-8358
Houston Methodist Hospital
Houston Texas, 77030, United States More Info
Sherif Nagueh, Site 0017
Contact
713-441-2850
Intermountain Medical Center
Murray Utah, 84107, United States More Info
Kia Afshar, Site 0035
Contact
801-507-3500
Local Institution - 0077
Ciudad De Cordoba Cordoba, X5000, Argentina More Info
Site 0077
Contact
Local Institution - 0082
Darlinghurst New South Wales, 2010, Australia
Local Institution - 0022
Herston Queensland, 4029, Australia
Local Institution - 0057
Klagenfurt am Wörthersee Kärnten, 9020, Austria
Local Institution - 0032
Braunau am Inn Upper Austria, 5280, Austria
Local Institution - 0028
Graz , 8036, Austria
Local Institution - 0088
Wien , 1090, Austria
Local Institution - 0007
Wien , 1100, Austria
Local Institution - 0084
Anderlecht Brussels, 1070, Belgium
Local Institution - 0070
Bruxelles Brussels, 1200, Belgium
Local Institution - 0069
Jette Brussels, 1090, Belgium
Local Institution - 0092
Genk Limburg, 3600, Belgium
Local Institution - 0083
Leuven Vlaams Brabant, 3000, Belgium
Local Institution - 0071
Roeselare West-Vlaanderen, 8800, Belgium
Local Institution - 0004
Calgary Alberta, T2N 1, Canada
Local Institution - 0016
Broumov Královéhradecký Kraj, 550 0, Czechia
Local Institution - 0053
Trinec Moravskoslezský Kraj, 739 6, Czechia
Local Institution - 0050
Prague Praha, Hlavní Mesto, 140 2, Czechia
Local Institution - 0011
Praha 2 Praha, Hlavní Mesto, 128 2, Czechia
Local Institution - 0052
Brno , 656 9, Czechia
Local Institution - 0073
Helsinki Etelä-Suomen Lääni, 00290, Finland
Local Institution - 0072
Turku Länsi-Suomen Lääni, 20540, Finland
Local Institution - 0031
Grenoble , 38043, France
Local Institution - 0014
Paris , 75015, France
Local Institution - 0026
Pessac , 33604, France
Local Institution - 0002
Rennes , 35000, France
Local Institution - 0047
Giessen Hessen, 35392, Germany
Local Institution - 0034
Göttingen Niedersachsen, 37075, Germany
Local Institution - 0040
Bad Oeynhausen Nordrhein-Westfalen, 32545, Germany
Local Institution - 0023
Berlin , 12203, Germany
Local Institution - 0008
Athina Attiki, 176 7, Greece
Local Institution - 0059
Chaidari, Athens Attiki, 124 6, Greece
Local Institution - 0009
Athens , 11527, Greece
Local Institution - 0037
Heraklion , 71110, Greece
Local Institution - 0006
Thessaloniki , 546 3, Greece
Local Institution - 0021
Thessaloniki , 54642, Greece
Local Institution - 0042
Pécs Baranya, 7621, Hungary
Local Institution - 0054
Szeged Csongrád, 6720, Hungary
Local Institution - 0020
Balatonfüred Veszprém, 8230, Hungary
Local Institution - 0019
Budapest , 1083, Hungary
Local Institution - 0013
Budapest , 1096, Hungary
Local Institution - 0041
Budapest , 1097, Hungary
Local Institution - 0063
Budapest , 1134, Hungary
Local Institution - 0038
Milano Lombardia, 20149, Italy
Local Institution - 0060
Milano Lombardia, 20162, Italy
Local Institution - 0056
Pavia Lombardia, 27100, Italy
Local Institution - 0048
Firenze Toscana, 50139, Italy
Local Institution - 0062
Massa Toscana, 54100, Italy
Local Institution - 0051
Arezzo , 52100, Italy
Local Institution - 0018
Warszawa Mazowieckie, 02-50, Poland
Local Institution - 0094
Warszawa Mazowieckie, 04-62, Poland
Local Institution - 0044
Katowice Slaskie, 40-55, Poland
Local Institution - 0049
Zabrze Slaskie, 41-80, Poland
Local Institution - 0012
Lódz , 93-33, Poland
Local Institution - 0043
Palma de Mallorca Baleares, 07198, Spain
Local Institution - 0046
Malaga Málaga, 29010, Spain
Local Institution - 0030
Barcelona , 08035, Spain
Local Institution - 0089
Madrid , 28034, Spain
Local Institution - 0081
Madrid , 28035, Spain
Local Institution - 0045
Salamanca , 37007, Spain
Local Institution - 0039
Sevilla , 41013, Spain
Local Institution - 0029
Lugano Ticino (it), 6900, Switzerland More Info
Site 0029
Contact
Local Institution - 0055
Lugano Ticino (it), 6900, Switzerland
Local Institution - 0036
Bern , 3010, Switzerland
Local Institution - 0061
Geneva , 1205, Switzerland More Info
Site 0061
Contact
Local Institution - 0058
Luzern , 6004, Switzerland
Local Institution - 0010
London , SW17 , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Hypertrophic Cardiomyopathy

Phase:

Phase 4

Estimated Enrollment:

100

Study ID:

NCT06112743

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.